https://indianpedia.org/index.php?action=history&feed=atom&title=Cadila_HealthcareCadila Healthcare - Revision history2026-07-31T12:38:27ZRevision history for this page on the wikiMediaWiki 1.45.4https://indianpedia.org/index.php?title=Cadila_Healthcare&diff=110659&oldid=prev2405:201:D002:3B6F:4168:7F85:59F5:7054 at 13:47, 27 May 20212021-05-27T13:47:51Z<p></p>
<p><b>New page</b></p><div>{{Short description|Indian multinational pharmaceutical company}}<br />
{{Use dmy dates|date=August 2018}}<br />
{{Use Indian English|date=August 2018}}<br />
{{Infobox company<br />
| name = Cadila Healthcare Limited<br />
| image = Cadila Healthcare Logo.png<br />
| type = [[Public company|Public]]<br />
| traded_as = {{ubl|{{BSE|532321}}|{{NSE|CADILAHC}}}}<br />
| founder = [[Ramanbhai Patel]]<br />
| key_people = Pankaj R. Patel, Chairman <br /> Sharvil P. Patel, MD<br />
| industry = [[Pharmaceutical industry|Pharmaceuticals]]<br />
| products = {{hlist|[[Pharmaceutical]]s |[[generic drug]]s |[[over-the-counter drug]]s |[[vaccine]]s |[[Medical diagnosis|diagnostics]] |[[contact lens]]es |[[Veterinary medicine|animal health]] }} <br />
| revenue = {{profit}} {{INRConvert|15139|c}} (FY 2021)<ref name=finance>{{cite web|title=Audited Financial Results For The Year Ended March 31, 2021|url=https://www.bseindia.com/xml-data/corpfiling/AttachLive/1daa76e1-3654-463c-9446-035ed5a87fe4.pdf|publisher=BSE|access-date=27 May 2021}}</ref><br />
| net_income = {{profit}} {{INRConvert|2133|c}} (FY 2021)<ref name=finance/><br />
| num_employees = 25,000 (2021)<ref name=finance/><br />
| foundation = {{Start date and age|1952|p=y}}<br />
| location = [[Ahmedabad]], [[Gujarat]], India<br />
| homepage = {{URL|http://www.zyduscadila.com/}}<br />
}}<br />
<br />
'''Cadila Healthcare Limited''' (also known as Zydus Cadila) is an [[India|Indian multinational]] [[pharmaceutical]] company headquartered in [[Ahmedabad]], [[Gujarat]], India primarily engaged in the manufacture of [[generic drugs]].<ref name="The Hindu Business Line">{{Cite news|url=http://www.thehindubusinessline.com/companies/announcements/others/zydus-launches-sovihep-the-breakthrough-therapy-for-hepatitis-c-in-alliance-with-gilead-sciences/article7003039.ece|title=Zydus launches SoviHep - the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences|date=2015-03-17|work=The Hindu Business Line|access-date=2017-12-29|language=en}}</ref><ref name="mapsofindia">{{cite web|date=21 June 2011|title=A Complete Overview on Cadila Healthcare, a growing and popular company in India.|url=http://business.mapsofindia.com/sectors/manufacturing/cadila-healthcare.html|access-date=2009-02-04|website=business.mapsofindia.com}}</ref><ref>{{Cite web|title=Cadila Healthcare Profit and Loss Reports - The Economic Times|url=https://economictimes.indiatimes.com/cadila-healthcare-ltd/profitandlose/companyid-3778.cms|access-date=2020-06-15|website=economictimes.indiatimes.com}}</ref> It ranked 100th in the [[Fortune India 500]] list in 2020.<ref>{{Cite web|title=Cadila Healthcare - Fortune 500 List 2020 - Fortune India|url=https://www.fortuneindia.com/fortune-500/company-list/cadila-healthcare?year=2020|access-date=2021-01-12|website=www.fortuneindia.com|language=en}}</ref><br />
<br />
== History ==<br />
Cadila was founded in 1952 by [[Ramanbhai Patel]] (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner [[Indravadan Modi]]. It evolved over the next four decades into an established pharmaceutical company.<br />
<br />
In 1995 the Patel and Modi families split; the Modi family's share was moved into a new company called [[Cadila Pharmaceuticals|Cadila Pharmaceuticals Ltd.]], and Cadila Healthcare Ltd became the Patel family's holding company. Cadila Healthcare had its [[initial public offering]] on the [[Bombay Stock Exchange]] in 2000 as stock code 532321.<br />
<br />
In 2015 the company acquired another Indian pharmaceutical company called German Remedies. On 25 June 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) as part of Zydus Healthcare Brasil Ltda.<ref>[https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=35196980 Company Overview of Química e Farmacêutica Nikkho do Brasil Ltda] ''Bloomberg''</ref><br />
<br />
In 2010, Cadila Healthcare received a [[Wellcome Trust]] Award under the "R&D for Affordable Healthcare in India" initiative.<br />
<br />
In 2014, Cadila Healthcare launched the world's first ''[[adalimumab biosimilar]]'' under the brand name '''Exemptia''' at one-fifth the originator's price.<ref>[http://articles.economictimes.indiatimes.com/2014-12-09/news/56879703_1_rheumatoid-arthritis-first-biosimilar-humira Zydus Cadila launches biosimilar of AbbVie's Humira in India] ''The Economic Times'' 9 December 2014</ref><br />
Zydus Cadila Healthcare has also launched its first research based drug molecule Saroglitazar in treatment of Diabetic Dyslipidemia under brand name "Lipaglyn". SoviHep is the first sofosbuvir brand launched in India by Zydus in year 2015.<ref name="The Hindu Business Line"/><br />
<br />
In 2019, injectable [[ketorolac]] tromethamine manufactured by Zydus (Cadila Healthcare) was recalled due to microbial growth.<br />
<br />
In 2020, Zydus Cadila's drug Desidustat received approval by the [[Food and Drug Administration|USFDA]] to initiate clinical trials on [[cancer]] patients.<ref>[https://timesofindia.indiatimes.com/india/zydus-cadila-gets-usfda-nod-for-drug-trials-to-treat-chemotherapy-induced-anemia/articleshow/77121315.cms Zydus Cadila Desidustat Gets USFDA Nod To Initiate Clinical Trials On Cancer Patients] ''The Times Of India'' 23 July 2020</ref><br />
<br />
== Products ==<br />
From twenty five pharmaceutical production operations in India as well as a Zydus Cadila develops and manufactures a large range of pharmaceuticals as well as diagnostics, herbal products, skin care products and other OTC products. Starting from late 2015, having concluded a voluntary license agreement with [[Gilead Sciences|Gilead]], the company also produces the generics for hepatitis C treatment (i.e. [[sofosbuvir]], distributed under the brand name SoviHep).<ref>{{cite web|url=http://hep-c-news.com/hepatitis-c-treatment-in-india-for-less-than-1000/|title=Hepatitis C treatment in India for less than $1000|date=11 July 2016|website=hep-c-news.com|publisher=Hep C News|archive-url=https://web.archive.org/web/20160916124038/http://hep-c-news.com/blog/2016/07/11/hepatitis-c-treatment-in-india-for-less-than-1000/|archive-date=16 September 2016|url-status=dead}}</ref><br />
<br />
The company makes [[active pharmaceutical ingredient]]s at three sites in India, Ankleshwar plants, Vadodara plant, and Patalganga plant.<br />
<br />
==COVID-19 vaccine development==<br />
In July 2020, the company got permission to conduct human trials of the developmental COVID-19 vaccine named '''[[ZyCoV-D]]''', from the [[Drugs Controller General of India]] (DCGI), Government of India.<ref>{{cite news |title=Potential COVID-19 vaccine by Zydus Cadila gets DCGI nod for human clinical trials |url=https://www.thehindu.com/sci-tech/health/potential-covid-19-vaccine-by-zydus-cadila-gets-dcgi-nod-for-human-clinical-trials/article31977556.ece |work=The Hindu |date=3 July 2020 |language=en-IN}}</ref><ref>{{cite news |title=Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate - ET HealthWorld |url=https://health.economictimes.indiatimes.com/news/pharma/zydus-cadila-begins-human-clinical-trials-of-covid-19-vaccine-candidate/76975377 |work=ETHealthworld.com |language=en}}</ref><ref>{{cite news |title=Zydus Cadila's COVID-19 Vaccine Candidate Found Safe in Early-Stage Human Trial |url=https://www.nytimes.com/reuters/2020/08/05/world/asia/05reuters-health-coronavirus-zydus-vaccine.html |work=The New York Times |date=5 August 2020}}</ref> It will be hitting the markets by June 2021.<ref>{{Cite web|date=2021-05-08|title=Cadila eyes nod for its vaccine by June|url=https://www.financialexpress.com/lifestyle/health/cadila-eyes-nod-for-its-vaccine-by-june/2248060/|access-date=2021-05-24|website=The Financial Express|language=en-US}}</ref><br />
<br />
Cadila is also among the several Indian pharma companies that received the licensing agreements from the [[Gilead Sciences]] to produce ''remdesivir''.<ref>{{cite news |last1=Umarji |first1=Vinay |title=Gilead finds fourth partner for manufacture of Remdesivir in Zydus Cadila |url=https://www.business-standard.com/article/companies/gilead-finds-fourth-partner-for-manufacture-of-remdesivir-in-zydus-cadila-120061201687_1.html |work=Business Standard India |date=12 June 2020}}</ref><br />
<br />
== Corporate control ==<br />
Zydus Cadila's major shareholder remains the Patel family. [[Pankaj Patel]] (born 1953), son of the founder, is the chairman of the company. In 2004, Pankaj Patel was included in ''[[Forbes|Forbes'<nowiki/>]]'' annual list of India's richest people. As of 2020, ''Forbes'' estimates Patel's net worth at US $3.9 billion, making him India's 46th richest person.<ref>{{Cite web|title=Pankaj Patel|url=https://www.forbes.com/profile/pankaj-patel/|access-date=2020-06-15|website=Forbes}}</ref><br />
<br />
== References ==<br />
{{Reflist}}<br />
<br />
==External links==<br />
* {{Official website|www.zyduscadila.com}}<br />
<br />
{{Nifty 200 companies}}<br />
<br />
{{Authority control}}<br />
<br />
[[Category:Companies listed on the Bombay Stock Exchange]]<br />
[[Category:Pharmaceutical companies of India]]<br />
[[Category:Manufacturing companies based in Ahmedabad]]<br />
[[Category:Health care companies of India]]<br />
[[Category:Pharmaceutical companies established in 1952]]<br />
[[Category:1952 establishments in Bombay State]]<br />
[[Category:Indian companies established in 1952]]</div>2405:201:D002:3B6F:4168:7F85:59F5:7054